Hepatitis C - pegylated interferons, ribavirin and alfa interferon

Summary

Guidance currently being reviewed: See review

This guidance replaces Hepatitis C - alpha interferon and ribavirin (TA14). This guidance is extended by Hepatitis C - peginterferon alfa and ribavirin(TA106)

Documents

For healthcare professionals

• TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Guidance
• TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Quick reference guide

For patients, carers and the public

• TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Information for the public

Background information

• Review Proposal - March 2008
• TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Distribution list
• 2004/005 People with chronic hepatitis C to benefit from guidance on new drugs and treatments
• Health Technology Assessment: Interferon alpha (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C
• Review decision: August 2008

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• None found